Author

T. Besson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Kumar· 1 shared C. Hurtz· 1 shared G. Wertheim· 1 shared H. Geng· 1 shared J. Chukinas· 1 shared J. D. Crispino· 1 shared J. P. Loftus· 1 shared J. Shi· 1 shared

Activity by Year

2022-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Kumar

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Pharmacologic Inhibition of DYRK1A Results in MYC Hyperactivation and ERK Hyperphosphorylation rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition

C. Hurtz, V. S. S. A. Ayyadevara, G. Wertheim, J. Chukinas, J. P. Loftus, S. J. Lee, A. Kumar, R. S. Bhansali, S. Swaminathan, H. Geng, T. Milne, X. Hua, K. M. Bernt, T. Besson, J. Shi, , S. K. Tasian

This study shows that inhibiting DYRK1A in KMT2A-R ALL cells leads to MYC upregulation and ERK hyperphosphorylation, making them sensitive to BCL2 inhibition.

bioRxiv · Oct 2, 2022 · PreprintCancer Biology